Caredx announces district court judge bars natera from falsely advertising and overstating the scientific performance of its prospera transplant test

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the united states district court for the district of delaware (the “district court”) issued an injunction prohibiting natera (nasdaq: ntra) from continuing to falsely advertise and overstate the scientific performance of its.
CDNA Ratings Summary
CDNA Quant Ranking